
|Videos|April 29, 2014
GVAX for Patients With Pancreatic Cancer
Author(s)Smitha Krishnamurthi, MD
Smitha Krishnamurthi, MD, associate professor of medicine, Case Western Reserve University, describes GVAX for patients with metastatic pancreatic adenocarcinoma.
Advertisement
Clinical Pearls
Smitha Krishnamurthi, MD, associate professor of medicine, Case Western Reserve University, describes GVAX for patients with metastatic pancreatic adenocarcinoma. A phase II study of the vaccine waspresented at the 2014 Gastrointestinal Cancers Symposium.
- GVAX is a whole cell vaccine made of pancreatic cancer cells expressing GM-CSF. GVAX is given with low-dose cyclophosphamide.
- Patients in the study were randomized to receive cyclophosphamide/GVAX followed by CRS-207 or just cyclophosphamide/GVAX. CRS-207 is a modified Listeria bacteria which expresses mesothelin.
- Patients in the cyclophosphamide/GVAX and CRS-207 arm experienced an overall survival benefit of about 2 months (6.1 versus 3.9 months).
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5








































